Baillie Gifford & Co’s Quest Diagnostics DGX Stock Holding History

Baillie Gifford & Co’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-171	Closed	-$24.2K	–	337
2023 Q1	$24.2K	Buy	171 +26	+18%	+$3.72K	﹤0.01%	327
2022 Q4	$22.7K	Hold	145	–	–	﹤0.01%	332
2022 Q3	$18K	Hold	145	–	–	﹤0.01%	348
2022 Q2	$19K	Hold	145	–	–	﹤0.01%	344
2022 Q1	$20K	Hold	145	–	–	﹤0.01%	363
2021 Q4	$25K	Hold	145	–	–	﹤0.01%	349
2021 Q3	$21K	Sell	145 -15	-9%	-$2.19K	﹤0.01%	366
2021 Q2	$21K	Hold	160	–	–	﹤0.01%	349
2021 Q1	$21K	Buy	160 +12	+8%	+$1.48K	﹤0.01%	327
2020 Q4	$18K	Buy	+148	New	+$18K	﹤0.01%	331
2013 Q4	–	Sell	-2,665	Closed	-$165K	–	210
2013 Q3	$165K	Hold	2,665	–	–	﹤0.01%	197
2013 Q2	$162K	Buy	+2,665	New	+$159K	﹤0.01%	173

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Baillie Gifford & Co's DGX Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Quest Diagnostics (DGX) in Q2 2023, closing a stake of 171 shares — an estimated $24.2K sold.

Baillie Gifford & Co first reported a position in DGX in Q2 2013 and held it in 12 quarters. The position peaked at $165K in Q3 2013. 818 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

Baillie Gifford & Co reported no remaining Quest Diagnostics position as of Q2 2023 after selling out during the quarter.
Baillie Gifford & Co sold 171 Quest Diagnostics shares in Q2 2023, an estimated $24.2K.
Baillie Gifford & Co first reported a position in Quest Diagnostics in Q2 2013 and held it in 12 quarters.
Baillie Gifford & Co's Quest Diagnostics position peaked at $165K in Q3 2013.
818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.